Posted by Michael Wonder on 21 Feb 2025
Epkinly (epcoritamab) approved by Japan Ministry of Health, Labour and Welfare for additional indication as a treatment for relapsed or refractory follicular lymphoma
20 February 2025 - Approval based on results from two Phase 1/2 EPCORE clinical trials, which demonstrated strong and durable efficacy in patients with relapsed or refractory follicular lymphoma who had received two or more lines of systemic therapy.
Genmab announced today that the Japan Ministry of Health, Labour and Welfare has approved Epkinly (epcoritamab) for the treatment of patients with relapsed or refractory follicular lymphoma (grades 1 to 3A) who have received two or more prior lines of therapy.
